Skip to main content
. Author manuscript; available in PMC: 2021 Mar 1.
Published in final edited form as: Clin Immunol. 2020 Feb 5;212:108360. doi: 10.1016/j.clim.2020.108360

Fig. 5: Peripheral blood- and synovial tissue-derived recombinant antibodies bind citrullinated antigens.

Fig. 5:

Reactivity of recombinant antibodies (rAbs) derived from peripheral blood (PB) and synovial tissue (ST) is shown for (A) the CCP3.1 ELISA and (B) citrullinated and native peptides/proteins by planar antigen microarray. CCP3.1 ELISA activity cutoff (red dotted line) was determined based on negative control (Neg Ctrl) antibodies. (C) The number of HC V gene mutations varies across antibodies with different binding specificities: rAbs predominantly binding to citrullinated antigens by planar microarray (Cit-specific); rAbs predominantly binding non-citrullinated antigens or exhibiting binding to both citrullinated and non-citrullinated antigens by planar microarray (Other Specificities); rAbs with no significant binding to any tested antigens (Nonreactive); rAbs that exhibit reactivity by CCP3.1 ELISA but do not exhibit reactivity to citrullinated antigens by planar microarray (CCP+/Array-). (* - p < 0.05, ANOVA followed by Tukey’s test).